Holen Sie sich die Stockscreener-App
17.21
4.81%
0.79
Handel nachbörslich:
17.20
-0.01
-0.06%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ARWR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$16.42
Offen:
$16.3
24-Stunden-Volumen:
2.59M
Relative Volume:
1.44
Marktkapitalisierung:
$2.38B
Einnahmen:
$181.74M
Nettoeinkommen (Verlust:
$-143.97M
KGV:
-12.38
EPS:
-1.39
Netto-Cashflow:
$9.60M
1W Leistung:
+4.52%
1M Leistung:
-6.01%
6M Leistung:
-8.89%
1J Leistung:
-26.48%
1-Tages-Spanne:
$15.81
$17.22
1-Wochen-Bereich:
$15.01
$17.22
52-Wochen-Spanne:
$9.57
$27.34
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Firmenname
Arrowhead Pharmaceuticals Inc
Sektor
Branche
Telefon
626-696-4702
Adresse
177 E COLORADO BLVD, PASADENA, CA
Vergleichen Sie ARWR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
17.21 | 2.27B | 181.74M | -143.97M | 9.60M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
374.46 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.94 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
435.00 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
638.90 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
289.75 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-05 | Eingeleitet | Goldman | Neutral |
| 2023-12-04 | Eingeleitet | BofA Securities | Buy |
| 2023-09-19 | Eingeleitet | Citigroup | Neutral |
| 2023-07-21 | Eingeleitet | TD Cowen | Outperform |
| 2023-05-12 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Outperform |
| 2023-04-12 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-11 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | Fortgesetzt | Goldman | Buy |
| 2021-08-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-11-19 | Eingeleitet | Citigroup | Buy |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-05-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-04-15 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | Eingeleitet | Goldman | Neutral |
| 2020-01-21 | Eingeleitet | SVB Leerink | Underperform |
| 2019-12-13 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-29 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-27 | Bestätigt | B. Riley FBR | Buy |
| 2019-11-25 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-10-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-09-07 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-08-08 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-07-02 | Bestätigt | Chardan Capital Markets | Buy |
Alle ansehen
Arrowhead Pharmaceuticals Inc Aktie (ARWR) Neueste Nachrichten
Healthcare Stocks Under the Spotlight: Eli Lilly & Co, Arrowhead Pharmaceuticals, and Travere Therapeutics - AInvest
Arrowhead reports Q3 EPS ($1.26), consensus ($1.10) - TipRanks
ARWR: Countdown to Nov. 18, 2025 PDUFA for Plozasiran for FCS - Research Tree
Is Arrowhead Pharmaceuticals Inc. trending in predictive chart modelsStock Market Watch with Smart Filters - Newser
Arrowhead hits the skids due to partnership with Sarepta - MSN
Arrowhead Pharmaceuticals: A High-Conviction Biotech Play with Multi-Billion-Dollar Potential - AInvest
Quoin (QNRX) Q2 Loss Beats Estimates - AOL.com
Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $45 - 富途牛牛
A Quick Look at Today's Ratings for Arrowhead Pharmaceuticals(ARWR.US), With a Forecast Between $29 to $45 - 富途牛牛
1 Small-Cap Biotech Stock Poised for a Breakout - AOL.com
Arrowhead Pharma stock price target lowered to $21 at Leerink Partners - Investing.com Canada
Arrowhead Pharmaceuticals: Balancing Promising Launch Preparations with Pipeline Uncertainties - TipRanks
Earnings call transcript: Arrowhead Pharma Q3 2025 misses forecasts - Investing.com
Earnings call transcript: Arrowhead Pharma Q3 2025 misses forecasts By Investing.com - Investing.com Canada
Arrowhead (ARWR) Q3 Revenue Drops 41% - AOL.com
Arrowhead Pharmaceuticals: Navigating a Narrowing Loss and a Pivotal Regulatory Timeline for Plozasiran - AInvest
Arrowhead Pharmaceuticals Fiscal Q3 Loss Narrows, Reports Revenue - MarketScreener
Arrowhead Pharmaceuticals Advances RNAi Therapeutics Pipeline - TipRanks
Coherus (CHRS) Q2 Revenue Jumps 10% - AOL.com
Arrowhead Pharmaceuticals Inc (ARWR) Q3 2025 Earnings Call Highl - GuruFocus
Decoding Arrowhead Pharmaceuticals Inc (ARWR): A Strategic SWOT Insight - GuruFocus
Arrowhead Pharmaceuticals: Buy Rating Affirmed on Promising Pipeline and Late-Stage Developments - TipRanks
Arrowhead Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Arrowhead (ARWR) Q3 2025 Earnings Call Transcript - Mitrade
ARROWHEAD PHARMACEUTICALS Earnings Results: $ARWR Reports Quarterly Earnings | ARWR Stock News - Quiver Quantitative
Arrowhead Pharmaceuticals Q3 Revenue Surpasses Expectations with $27.8mln, Sarepta Milestone Earnings $100mln. - AInvest
Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results - Business Wire
Arrowhead Pharmaceuticals shares fall 2.15% intraday as Sarepta Therapeutics reports strong earnings and resumes deliveries. - AInvest
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Arrowhead Pharmaceuticals (ARWR) Prepares for Q3 Earnings Report - GuruFocus
TR | OpenAI4o Maintains Arrowhead Pharmaceuticals(ARWR.US) With Hold Rating, Maintains Target Price $16.5 - 富途牛牛
Arrowhead sells rights of Hypertriglyceridemia candidate to Sanofi in Greater China for $265 M - BioSpectrum Asia
Arrowhead Pharmaceuticals, Inc. (ARWR) Secures $100M Milestone from Sarepta in RNAi Breakthrough Deal - MSN
Arrowhead sells China hypertriglyceridemia candidate rights to Sanofi - Yahoo Finance
Sanofi grabs Chinese rights to Arrowhead rare disease drug - pharmaphorum
Is Arrowhead Pharmaceuticals Inc. a growth stock or a value stockFree Daily Trading Room Entry - Jammu Links News
Is Arrowhead Pharmaceuticals Inc. stock overvalued or undervaluedAchieve breakthrough investment performance - Jammu Links News
When is Arrowhead Pharmaceuticals Inc. stock expected to show significant growthBuild a diversified portfolio for sustainable growth - Jammu Links News
How volatile is Arrowhead Pharmaceuticals Inc. stock compared to the marketAchieve breakthrough investment performance - Jammu Links News
Is it the right time to buy Arrowhead Pharmaceuticals Inc. stockPhenomenal returns - Jammu Links News
What are the latest earnings results for Arrowhead Pharmaceuticals Inc.Achieve consistent high returns with low risk - Jammu Links News
Why is Arrowhead Pharmaceuticals Inc. stock attracting strong analyst attentionCapitalize on emerging investment opportunities - Jammu Links News
Should I hold or sell Arrowhead Pharmaceuticals Inc. stock in 2025Unlock powerful trading strategies for gains - Jammu Links News
What are Arrowhead Pharmaceuticals Inc. company’s key revenue driversBreakthrough wealth creation - Jammu Links News
What analysts say about Arrowhead Pharmaceuticals Inc. stockOutstanding yields - Jammu Links News
How does Arrowhead Pharmaceuticals Inc. compare to its industry peersMaster the art of timing market moves - Jammu Links News
What drives Arrowhead Pharmaceuticals Inc. stock priceUnlock powerful portfolio optimization tools - Jammu Links News
What are analysts’ price targets for Arrowhead Pharmaceuticals Inc. in the next 12 monthsFree Predictions - Jammu Links News
Arrowhead Pharmaceuticals Sells Rights to Sanofi for Plozasiran in Greater China - AInvest
What is the dividend policy of Arrowhead Pharmaceuticals Inc. stockPost Market Watchlist For Every Investor - Jammu Links News
Arrowhead Pharmaceuticals Inc. Price Holds Above Key Fib LevelShort Term High Yield Stock Tips for Active Traders - metal.it
Finanzdaten der Arrowhead Pharmaceuticals Inc-Aktie (ARWR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Arrowhead Pharmaceuticals Inc-Aktie (ARWR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Anzalone Christopher Richard | Chief Executive Officer |
Apr 11 '25 |
Sale |
11.49 |
50,800 |
583,692 |
3,921,255 |
| Anzalone Christopher Richard | Chief Executive Officer |
Apr 10 '25 |
Sale |
10.87 |
50,000 |
543,500 |
3,972,055 |
| Anzalone Christopher Richard | Chief Executive Officer |
Apr 09 '25 |
Sale |
10.07 |
40,322 |
406,145 |
4,022,055 |
3.70%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):